Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis

Summary

This is a retreatment, multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of Benvitimod cream, 1% twice daily for the retreatment of mild to moderate stable psoriasis vulgaris in adults. Approximately 390 participants with mild to moderate stable psoriasis vulgaris will be enrolled and randomly divided into two groups in a 2:1 ratio. They will use either the Benvitimod cream or placebo at the skin with psoriasis vulgaris for 12 weeks.

Timeline

Start

2022-04

Primary completion

2023-06

Completion

2023-08

Drugs

Indications